The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...

Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.

Detailed data will be presented at a future medical meeting and submitted for regulatory review later this year.

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate ...

Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive mHSPC: Basel Tuesday, June 3, 2025, 12:00 Hrs [IST] ...

Novartis admitted the email broke several rules set out in the U.K. marketing code. In a long response to the PMCPA, the ...

Find insight on Novarti, Sanofi and more in the latest Market Talks covering Health Care.

Investing.com -- Novartis (SIX: NOVN) on Monday said that its cancer drug Pluvicto showed positive results in a late-stage ...

The latest results, which J&J shared at the 2025 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this ...

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an ...